•
Dec 31, 2024

3D Systems Q4 2024 Earnings Report

3D Systems reported a revenue decline and a net loss in Q4 2024, impacted by a change in accounting estimates in its Regenerative Medicine program.

Key Takeaways

3D Systems' Q4 2024 revenue fell 3% year-over-year to $111 million, largely due to an $8.7 million adjustment tied to its Regenerative Medicine program. The company posted a net loss of $33.7 million and continued efforts to cut costs, while non-GAAP EPS came in at -$0.19.

Q4 revenue declined 3% year-over-year to $111 million.

Reported EPS was -$0.25; non-GAAP EPS was -$0.19.

Gross profit margin decreased to 31.0% from 38.3% last year.

Healthcare revenue dropped 21% while Industrial revenue rose 11%.

Total Revenue
$111M
Previous year: $115M
-3.4%
EPS
-$0.19
Previous year: -$0.11
+72.7%
31%
Previous year: 38.3%
-19.1%
31.3%
Previous year: 39.8%
-21.4%
Gross Profit
$34.4M
Previous year: $46.3M
-25.8%
Cash and Equivalents
$171M
Previous year: $332M
-48.3%
Free Cash Flow
-$13.1M
Previous year: -$15M
-12.5%
Total Assets
$609M
Previous year: $980M
-37.9%

3D Systems

3D Systems

3D Systems Revenue by Segment

Forward Guidance

3D Systems expects flat to modest revenue growth for FY2025, aiming for break-even or better adjusted EBITDA by Q4.

Positive Outlook

  • New products gaining traction in Healthcare and Industrial markets.
  • Full-year 2025 revenue expected to reach $420M to $435M.
  • Cost reduction plan expected to deliver $50M in annual savings.
  • Geomagic platform divestiture to boost cash reserves.
  • Improved utilization rates in installed printer base.

Challenges Ahead

  • Accounting estimate change negatively impacted Q4 results.
  • Healthcare segment revenue declined sharply year-over-year.
  • Operating loss and adjusted EBITDA remained negative.
  • Macroeconomic uncertainty impacting capital spending.
  • Full impact of cost-saving initiatives won’t materialize until mid-2026.

Revenue & Expenses

Visualization of income flow from segment revenue to net income